Yahoo
NYSE - Nasdaq Real Time Price USD

Danaher Corporation (DHR)

235.36 +1.29 (+0.55%)
As of 10:04:43 AM EDT. Market Open.
Trade Danaher on Coinbase

Key Executives

Amounts are as of December 31, 2025 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.
Name Title Pay Exercised Year Born
Mr. Steven M. Rales
Co-Founder & Chairman -- -- 1951
Ms. Julie Sawyer Montgomery
President, CEO & Director 2.58M -- 1972
Mr. Mitchell P. Rales
Co-Founder & Director -- -- 1957
Dr. Jose-Carlos Gutierrez-Ramos Ph.D.
Senior VP & Chief Science Officer 2.52M -- 1962
Mr. Matthew R. McGrew
Executive Vice President 3.17M 2.45M 1972
Mr. Rainer M. Blair
Senior Advisor 6.12M -- 1964
Mr. Christopher Paul Riley
Executive VP of Biotechnology Group & CEO of Cytiva 2.54M 947.66k 1974
Mr. Matthew E. Gugino C.F.A., CPA
Executive VP & CFO -- -- 1983
Mr. Christopher M. Bouda
VP & Chief Accounting Officer -- -- --
Ms. Rachel Marie Vatnsdal Olson
Vice President of Investor Relations -- -- --

Danaher Corporation

2200 Pennsylvania Avenue N.W.
Suite 800W
Washington, DC 20037-1701
United States
202 828 0850 https://www.danaher.com
Sector: 
Healthcare
Full Time Employees: 
58,000

Description

Danaher Corporation designs, manufactures, and markets professional, medical, research, and industrial products and services in the United States, China, and internationally. The company operates through Biotechnology, Life Sciences, and Diagnostics segments. The Biotechnology segment provides technologies, consumables, services, and solutions that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, and aseptic fill finish; single-use hardware, consumables, and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services for diagnostic and assay development; and healthcare filtration solutions. The Life Sciences segment provides mass spectrometers; bioanalytical measurement systems; flow cytometry, genomics, lab automation, centrifugation, liquid handling automation instruments, antibodies and reagents, and particle counting and characterization; genome sample preparation; microscopes; protein consumables; filtration products; and genomic medicines, such as custom nucleic acid products, and plasmid DNA, RNA, and proteins under the ABCAM, ALDEVRON, BECKMAN COULTER, GENEDATA, IDT, LEICA MICROSYSTEMS, MOLECULAR DEVICES, PALL, PHENOMENEX, and SCIEX brands. The Diagnostics segment offers clinical instruments, consumables, software, and services that hospitals, physicians' offices, reference laboratories and other critical care settings use to diagnose disease and make treatment decisions. The company was formerly known as Diversified Mortgage Investors, Inc. and changed its name to Danaher Corporation in 1984. Danaher Corporation was incorporated in 1969 and is headquartered in Washington, the District Of Columbia.

Corporate Governance

Danaher Corporation’s ISS Governance QualityScore as of October 1, 2026 is 7. The pillar scores are Audit: 6; Board: 10; Shareholder Rights: 2; Compensation: 5.
Corporate governance scores courtesy of Institutional Shareholder Services (ISS) Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.

Upcoming Events

October 21, 2026 at 12:30 PM UTC

Danaher Corporation Earnings Date

October 30, 2026 at 12:00 AM UTC

Dividend Date

Recent Events

October 21, 2026 at 12:00 AM UTC

8-K: Corporate Changes & Voting Matters

October 13, 2026 at 12:00 AM UTC

8-K: Corporate Changes & Voting Matters

September 30, 2026 at 12:00 AM UTC

25-NSE: Notification filed by national security exchange to report the removal from listing and registration of matured

September 30, 2026 at 12:00 AM UTC

Ex-Dividend Date

August 3, 2026 at 12:00 AM UTC

8-K: Corporate Changes & Voting Matters

July 21, 2026 at 12:00 AM UTC

8-K: Corporate Changes & Voting Matters

June 16, 2026 at 12:00 AM UTC

11-K: Annual report of employee stock purchase

June 9, 2026 at 12:00 AM UTC

S-8: Offering Registrations

June 3, 2026 at 12:00 AM UTC

8-K: Corporate Changes & Voting Matters

May 12, 2026 at 12:00 AM UTC

SD: Specialized Disclosure Report filed pursuant to Section 1502 of the Dodd-Frank Wall Street Reform and Consumer Protection Act relating to the use of conflict minerals (Rule 13p-1)

Related Tickers

Mobilize your Website
View Site in Mobile | Classic
Share by: